Nocturnal Glucose Metabolism in Type 1 Diabetes: A Study Comparing Single Versus Dual Tracer Approaches

Ashwini Mallad, Ling Hinshaw, Chiara Dalla Man, Claudio Cobelli, Rita Basu, Ravi Lingineni, Rickey E. Carter, Yogish C Kudva, Ananda Basu

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Understanding the effect size, variability, and underlying physiology of the dawn phenomenon is important for next-generation closed-loop control algorithms for type 1 diabetes (T1D). Subjects and Methods: We used an iterative protocol design to study 16 subjects with T1D on individualized insulin pump therapy for two successive nights. Endogenous glucose production (EGP) rates at 3 a.m. and 7 a.m. were measured with [6,6-<sup>2</sup>H<inf>2</inf>]glucose as a single tracer, infused from midnight to 7 a.m. in all subjects. To explore possibility of tracer recycling due to prolonged [6,6-<sup>2</sup>H<inf>2</inf>]glucose infusion, which was highly probable after preplanned interim data analyses, we infused a second tracer, [6-<sup>3</sup>H]glucose, from 4 a.m. to 7 a.m. in the last seven subjects to measure EGP at 7 a.m. Results: Cortisol concentrations increased during both nights, but changes in glucagon and insulin concentration were inconsistent. Although the plasma glucose concentrations rose from midnight to 7 a.m. during both nights, EGP measured with [6,6-<sup>2</sup>H<inf>2</inf>]glucose between 3 a.m. and 7 a.m. did not differ during Night 1 but fell in Night 2. However, EGP measured with [6-<sup>3</sup>H]glucose at 7 a.m. was higher than that measured with [6,6-<sup>2</sup>H<inf>2</inf>]glucose during both nights, thereby suggesting tracer recycling probably underestimating EGP calculated at 7 a.m. with [6,6-<sup>2</sup>H<inf>2</inf>]glucose. Likewise, EGP was higher at 7 a.m. with [6-<sup>3</sup>H]glucose than at 3 a.m. with [6,6-<sup>2</sup>H<inf>2</inf>]glucose during both nights. Conclusions: The data demonstrate a consistent overnight rise in glucose concentrations through increased EGP, mediated likely by rising cortisol concentrations. The observations with the dual tracer approach imply significant tracer recycling leading to underestimation of EGP measured by longer-duration tracer infusion.

Original languageEnglish (US)
Pages (from-to)587-595
Number of pages9
JournalDiabetes Technology and Therapeutics
Volume17
Issue number8
DOIs
StatePublished - Aug 1 2015

Fingerprint

Type 1 Diabetes Mellitus
Glucose
Recycling
Hydrocortisone
Insulin
Glucagon

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medical Laboratory Technology

Cite this

Mallad, A., Hinshaw, L., Dalla Man, C., Cobelli, C., Basu, R., Lingineni, R., ... Basu, A. (2015). Nocturnal Glucose Metabolism in Type 1 Diabetes: A Study Comparing Single Versus Dual Tracer Approaches. Diabetes Technology and Therapeutics, 17(8), 587-595. https://doi.org/10.1089/dia.2015.0011

Nocturnal Glucose Metabolism in Type 1 Diabetes : A Study Comparing Single Versus Dual Tracer Approaches. / Mallad, Ashwini; Hinshaw, Ling; Dalla Man, Chiara; Cobelli, Claudio; Basu, Rita; Lingineni, Ravi; Carter, Rickey E.; Kudva, Yogish C; Basu, Ananda.

In: Diabetes Technology and Therapeutics, Vol. 17, No. 8, 01.08.2015, p. 587-595.

Research output: Contribution to journalArticle

Mallad, Ashwini ; Hinshaw, Ling ; Dalla Man, Chiara ; Cobelli, Claudio ; Basu, Rita ; Lingineni, Ravi ; Carter, Rickey E. ; Kudva, Yogish C ; Basu, Ananda. / Nocturnal Glucose Metabolism in Type 1 Diabetes : A Study Comparing Single Versus Dual Tracer Approaches. In: Diabetes Technology and Therapeutics. 2015 ; Vol. 17, No. 8. pp. 587-595.
@article{3d6c199ad45842788e3f3796c12b5a85,
title = "Nocturnal Glucose Metabolism in Type 1 Diabetes: A Study Comparing Single Versus Dual Tracer Approaches",
abstract = "Background: Understanding the effect size, variability, and underlying physiology of the dawn phenomenon is important for next-generation closed-loop control algorithms for type 1 diabetes (T1D). Subjects and Methods: We used an iterative protocol design to study 16 subjects with T1D on individualized insulin pump therapy for two successive nights. Endogenous glucose production (EGP) rates at 3 a.m. and 7 a.m. were measured with [6,6-2H2]glucose as a single tracer, infused from midnight to 7 a.m. in all subjects. To explore possibility of tracer recycling due to prolonged [6,6-2H2]glucose infusion, which was highly probable after preplanned interim data analyses, we infused a second tracer, [6-3H]glucose, from 4 a.m. to 7 a.m. in the last seven subjects to measure EGP at 7 a.m. Results: Cortisol concentrations increased during both nights, but changes in glucagon and insulin concentration were inconsistent. Although the plasma glucose concentrations rose from midnight to 7 a.m. during both nights, EGP measured with [6,6-2H2]glucose between 3 a.m. and 7 a.m. did not differ during Night 1 but fell in Night 2. However, EGP measured with [6-3H]glucose at 7 a.m. was higher than that measured with [6,6-2H2]glucose during both nights, thereby suggesting tracer recycling probably underestimating EGP calculated at 7 a.m. with [6,6-2H2]glucose. Likewise, EGP was higher at 7 a.m. with [6-3H]glucose than at 3 a.m. with [6,6-2H2]glucose during both nights. Conclusions: The data demonstrate a consistent overnight rise in glucose concentrations through increased EGP, mediated likely by rising cortisol concentrations. The observations with the dual tracer approach imply significant tracer recycling leading to underestimation of EGP measured by longer-duration tracer infusion.",
author = "Ashwini Mallad and Ling Hinshaw and {Dalla Man}, Chiara and Claudio Cobelli and Rita Basu and Ravi Lingineni and Carter, {Rickey E.} and Kudva, {Yogish C} and Ananda Basu",
year = "2015",
month = "8",
day = "1",
doi = "10.1089/dia.2015.0011",
language = "English (US)",
volume = "17",
pages = "587--595",
journal = "Diabetes Technology and Therapeutics",
issn = "1520-9156",
publisher = "Mary Ann Liebert Inc.",
number = "8",

}

TY - JOUR

T1 - Nocturnal Glucose Metabolism in Type 1 Diabetes

T2 - A Study Comparing Single Versus Dual Tracer Approaches

AU - Mallad, Ashwini

AU - Hinshaw, Ling

AU - Dalla Man, Chiara

AU - Cobelli, Claudio

AU - Basu, Rita

AU - Lingineni, Ravi

AU - Carter, Rickey E.

AU - Kudva, Yogish C

AU - Basu, Ananda

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Background: Understanding the effect size, variability, and underlying physiology of the dawn phenomenon is important for next-generation closed-loop control algorithms for type 1 diabetes (T1D). Subjects and Methods: We used an iterative protocol design to study 16 subjects with T1D on individualized insulin pump therapy for two successive nights. Endogenous glucose production (EGP) rates at 3 a.m. and 7 a.m. were measured with [6,6-2H2]glucose as a single tracer, infused from midnight to 7 a.m. in all subjects. To explore possibility of tracer recycling due to prolonged [6,6-2H2]glucose infusion, which was highly probable after preplanned interim data analyses, we infused a second tracer, [6-3H]glucose, from 4 a.m. to 7 a.m. in the last seven subjects to measure EGP at 7 a.m. Results: Cortisol concentrations increased during both nights, but changes in glucagon and insulin concentration were inconsistent. Although the plasma glucose concentrations rose from midnight to 7 a.m. during both nights, EGP measured with [6,6-2H2]glucose between 3 a.m. and 7 a.m. did not differ during Night 1 but fell in Night 2. However, EGP measured with [6-3H]glucose at 7 a.m. was higher than that measured with [6,6-2H2]glucose during both nights, thereby suggesting tracer recycling probably underestimating EGP calculated at 7 a.m. with [6,6-2H2]glucose. Likewise, EGP was higher at 7 a.m. with [6-3H]glucose than at 3 a.m. with [6,6-2H2]glucose during both nights. Conclusions: The data demonstrate a consistent overnight rise in glucose concentrations through increased EGP, mediated likely by rising cortisol concentrations. The observations with the dual tracer approach imply significant tracer recycling leading to underestimation of EGP measured by longer-duration tracer infusion.

AB - Background: Understanding the effect size, variability, and underlying physiology of the dawn phenomenon is important for next-generation closed-loop control algorithms for type 1 diabetes (T1D). Subjects and Methods: We used an iterative protocol design to study 16 subjects with T1D on individualized insulin pump therapy for two successive nights. Endogenous glucose production (EGP) rates at 3 a.m. and 7 a.m. were measured with [6,6-2H2]glucose as a single tracer, infused from midnight to 7 a.m. in all subjects. To explore possibility of tracer recycling due to prolonged [6,6-2H2]glucose infusion, which was highly probable after preplanned interim data analyses, we infused a second tracer, [6-3H]glucose, from 4 a.m. to 7 a.m. in the last seven subjects to measure EGP at 7 a.m. Results: Cortisol concentrations increased during both nights, but changes in glucagon and insulin concentration were inconsistent. Although the plasma glucose concentrations rose from midnight to 7 a.m. during both nights, EGP measured with [6,6-2H2]glucose between 3 a.m. and 7 a.m. did not differ during Night 1 but fell in Night 2. However, EGP measured with [6-3H]glucose at 7 a.m. was higher than that measured with [6,6-2H2]glucose during both nights, thereby suggesting tracer recycling probably underestimating EGP calculated at 7 a.m. with [6,6-2H2]glucose. Likewise, EGP was higher at 7 a.m. with [6-3H]glucose than at 3 a.m. with [6,6-2H2]glucose during both nights. Conclusions: The data demonstrate a consistent overnight rise in glucose concentrations through increased EGP, mediated likely by rising cortisol concentrations. The observations with the dual tracer approach imply significant tracer recycling leading to underestimation of EGP measured by longer-duration tracer infusion.

UR - http://www.scopus.com/inward/record.url?scp=84938562603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938562603&partnerID=8YFLogxK

U2 - 10.1089/dia.2015.0011

DO - 10.1089/dia.2015.0011

M3 - Article

C2 - 26121060

AN - SCOPUS:84938562603

VL - 17

SP - 587

EP - 595

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

SN - 1520-9156

IS - 8

ER -